NRx Pharmaceuticals’ (NRXP) Buy Rating Reaffirmed at BTIG Research

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reaffirmed by equities research analysts at BTIG Research in a research note issued to investors on Monday, Benzinga reports. They currently have a $10.00 price objective on the stock. BTIG Research’s target price indicates a potential upside of 187.36% from the stock’s current price.

Other research analysts have also issued reports about the stock. Zacks Research lowered shares of NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Wednesday, August 26th. UBS Group reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 26th. Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Wednesday, August 5th. HC Wainwright reiterated a “buy” rating on shares of NRx Pharmaceuticals in a report on Tuesday, August 25th. Finally, Wall Street Zen downgraded NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Five investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $34.50.

NRx Pharmaceuticals Stock Up 2.4%

NASDAQ:NRXP traded up $0.08 during trading hours on Monday, hitting $3.48. 805,096 shares of the stock traded hands, compared to its average volume of 1,093,721. NRx Pharmaceuticals has a 1 year low of $1.62 and a 1 year high of $5.05. The stock has a 50 day moving average price of $3.63 and a 200 day moving average price of $3.18. The company has a market cap of $150.68 million, a price-to-earnings ratio of -6.33 and a beta of 2.19.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its earnings results on Friday, August 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.33). The company had revenue of $1.10 million during the quarter, compared to the consensus estimate of $1.33 million. Equities analysts forecast that NRx Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NRx Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Anson Funds Management LP increased its stake in NRx Pharmaceuticals by 50.3% during the 4th quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after purchasing an additional 1,018,853 shares in the last quarter. Vanguard Group Inc. lifted its position in NRx Pharmaceuticals by 18.3% during the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after acquiring an additional 82,781 shares during the period. AdvisorShares Investments LLC grew its stake in NRx Pharmaceuticals by 28.2% during the 1st quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock valued at $896,000 after purchasing an additional 92,463 shares during the last quarter. Commonwealth Equity Services LLC purchased a new stake in NRx Pharmaceuticals during the 4th quarter valued at about $994,000. Finally, Geode Capital Management LLC increased its holdings in shares of NRx Pharmaceuticals by 17.8% in the fourth quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock valued at $593,000 after purchasing an additional 33,004 shares during the period. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.